Skip to main content
OpenTrials

Clinical trial condition

Recurrent Differentiated Thyroid Gland Carcinoma

Explore clinical trials studying Recurrent Differentiated Thyroid Gland Carcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Differentiated Thyroid Gland Carcinoma trial results

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT02973997

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +38 more
Locations
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions